Current evaluation of alemtuzumab in multiple sclerosis.

about

Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.The transition from first-line to second-line therapy in multiple sclerosis.

P2860

Q38444543-4CE95630-F45F-4E1D-8020-C13992A31C6F Q41014662-F8FA5BD6-58DF-4DF3-8B25-927B4FAE5E0F

P2860

Current evaluation of alemtuzumab in multiple sclerosis.

Item

http://www.wikidata.org/entity/Q38167350

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current evaluation of alemtuzumab in multiple sclerosis.

@en

type

Item

label

Current evaluation of alemtuzumab in multiple sclerosis.

@en

prefLabel

Current evaluation of alemtuzumab in multiple sclerosis.

@en

P1476

Current evaluation of alemtuzumab in multiple sclerosis.

@en

P2093

Patricia Katherine Coyle

http://www.w3.org/2001/XMLSchema#string

P2860

Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Alemtuzumab therapy for multiple sclerosis.

P304

127-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2014.866084

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24289293

http://www.w3.org/2001/XMLSchema#string

Current evaluation of alemtuzumab in multiple sclerosis.

about

P2860

P2860

Current evaluation of alemtuzumab in multiple sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698